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The combination effect of docetaxel and capecitabine on tumour response rate and survival was demonstrated recently in metastatic
breast cancer patients. This combination was based on an experimental hypothesis that taxane can increase tumour sensitivity to the
effect of capecitabine through the upregulation of thymidine phosphorylase (TP), which is responsible for the metabolism of
5-fluorouracil (5-FU) and its derivatives, including capecitabine. To examine the alteration in TP expression before and after
neoadjuvant chemotherapy, 92 patients with primary breast cancer (T2-4N0-1M0) were enrolled in this study; 14 were treated with
adriamycin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC); 58 with 5-FU, adriamycin, and cyclophosphamide
(FAC) or 5-FU, epirubicin, and cyclophosphamide (FEC); and 20 with FEC followed by docetaxel/taxotere (TXT-containing regimen).
Thymidine phosphorylase upregulation was seen in 54.4% and 32.6% of patients in tumour cells and stromal cells, respectively.
Increases in TP expression were found only in the AC/EC and TXT-containing regimen groups. In conclusion, it was strongly
suggested that unlike 5-FU-containing regimens, the taxane and AC combination therapies upregulate TP expression in primary
breast cancer. Thymidine phosphorylase upregulation by several anticancer drugs implies the importance of individualised strategies
for sensitisation of tumour tissues to 5-FU and its derivatives.
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Thymidine phosphorylase (TP) is an enzyme that is responsible for
nucleoside metabolism, antiapoptosis activity, and promotion of
angiogenesis. Thymidine phosphorylase acts mainly in the salvage
cascade of DNA metabolism in response to various types of
stresses. Thymidine phosphorylase functions in the prevention of
hypoxia-induced apoptosis according to recent experimental
analyses (Ikeda et al, 2003). In addition, it has been documented
that a metabolite of thymidine generated by TP, 2-deoxy-D-ribose
(2-DDR), acts as a potent chemotactic factor on the endothelium,
which results in the promotion of neovascularisation (Haraguchi
et al, 1994). In fact, in a variety of tumour tissues, overexpression
of TP was found to correlate significantly with an increase in
neovascularisation (Toi et al, 1995; Tanigawa et al, 1996; Matsuura
et al, 1999) and poor prognosis (Maeda et al, 1996; Takebayashi
et al, 1996; Koukourakis et al, 1998; Toi et al, 1999).
The regulation of TP has been also studied from various points
of view. Generally, TP is upregulated by stress such as hypoxia
(Griffiths et al, 1997), radiation (Sawada et al, 1999), and
chemotherapeutic damage (Sawada et al, 1998; Endo et al, 1999).
Several types of cytokines such as interleukin (IL)-1, tumour
necrosis factor (TNF)-a, and interferon (IFN)-g also upregulate the
expression of TP in both nonmalignant and malignant cells (Eda
et al, 1993). Therefore, it is likely that these factors have important
functions in stress-induced TP upregulation.
Thymidine phosphorylase has also been studied as a key enzyme
involved in nucleoside metabolism. In particular, TP is known to
be essential for the activation of capecitabine from the inter-
mediate form 50-deoxy-5-fluorouridine (50-DFUR) to the active
form 5-fluorouracil (5-FU). Experimental studies showed that 50-
DFUR is much more active in TP-transfected cells than in mock-
transfected cells (Patterson et al, 1995; Evrard et al, 1999). It is also
true that 50-DFUR is more effective for TP-overexpressing tumour
xenografts than for tumour xenografts expressing normal or low
levels of TP (Morita et al, 2001; Ishikawa et al, 1998). Furthermore,
several preliminary studies also confirmed that TP expression in
tumour cells was a predictive factor for favourable prognosis in
cancer patients treated with 50-DFUR (Yamamoto et al, 1996; Ishii
et al, 1996; Koizumi et al, 1999; Nishimura et al, 2002). In primary
breast cancer, an analysis of the relationship between TP
expression and the therapeutic effect of 50-DFUR as a retrospective
study in a prospective clinical randomised study has recently been
reported, where patients who received no systemic adjuvant
treatment were compared with those who received treatment with
50-DFUR alone. It concluded that TP is a promising marker for
predicting the survival benefit from 50-DFUR treatment in early
breast cancer patients (Tominaga et al, 2002).
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lOn the other hand, a hypothesis that TP modulation could
enhance the therapeutic activity of 50-DFUR/capecitabine has been
tested at the experimental level. In various types of tumour
xenograft models, the combination of capecitabine and various TP
modulating chemotherapeutic agents achieved synergistic effects
(Sawada et al, 1998; Fujimoto-Ouchi et al, 2002). Differences in the
duration between the induction chemotherapy, with respect to TP
modulation, and capecitabine treatment elicited different tumour
responses, indicating that TP modulation is time dependent
(Fujimoto-Ouchi et al, 2001) and that the timing of capecitabine
treatment after the initial chemotherapy is important. In a clinical
situation, it was demonstrated that therapy with capecitabine plus
TXT achieved a significantly higher response and longer time to
progression (TTP) than TXT therapy alone in the first-line
treatment of metastatic breast cancer patients (O’Shaughnessy
et al, 2002). This clinical finding would reflect on the basic
hypothesis that TXT sensitises tumours to the effect of capecita-
bine. This suggests the importance of considering TP modulation
from the point of sensitising breast cancer tumours to 5-FU
derivatives such as capecitabine and 50-DFUR, because the
likelihood of their efficacy might be increased for TP upregulated
tumours.
Issues related to TP modulation in human tumour tissues,
however, are still largely unknown. Very few papers have touched
on this crucial question. Thus, in the present study, we examined
TP expression prior to and after the administration of chemother-
apy in a neoadjuvant setting of primary breast cancer treatment.
We will demonstrate that TP expression is modulated significantly
by certain chemotherapies in a defined patient population.
MATERIALS AND METHODS
Patient characteristics
Between January 1, 1998 and December 30, 2002, women at the
Tokyo Metropolitan Komagome Hospital and the National Kyushu
Cancer Hospital who had primary, palpable, operable breast
cancer (T2-4N0-1M0, according to the tumour, node, metastasis
staging system) were included in this study. All patients were
diagnosed by core needle biopsy or excisional biopsy prior to
starting chemotherapy, and all patients were informed about the
investigational nature of the study, which had been approved by
the institutional review board. Written informed consent was
obtained from each woman before entering her into the trial. All
patients received either partial mastectomy or modified radical
mastectomy with full dissection of axillary nodes after the
treatment by neoadjuvant chemotherapy. Both biopsied and
surgically resected samples were sufficient for accurate histological
diagnosis and measurement of biomarkers.
Treatment regimens
Patients were treated with anthracycline-containing regimens or a
taxane-containing regimen. The anthracycline-containing regi-
mens consisted of adriamycin (ADR) and cyclophosphamide
(CPA), (AC); epirubicin (EPI) and CPA (EC) or 5-FU, ADR, and
CPA (FAC); and 5-FU, EPI, and CPA (FEC). Patients were given
chemotherapy every 21 days with either the AC (ADR 50mgm
 2
and CPA 500mgm
 2), EC (EPI 75mgm
 2 and CPA 600mgm
 2),
FAC (5-FU 500mgm
 2, ADR 50mgm
 2, and CPA 500mgm
 2),
and FEC (5-FU 500mgm
 2, EPI 100mgm
 2, and CPA
500mgm
 2) or the TXT-containing regimen (FEC followed by
TXT 75mgm
 2 or TXT 60mgm
 2).
Efficacy assessment
Responses of the primary tumours to each chemotherapy regimen
were evaluated according to the criteria established by the
Japanese Breast Cancer Society (The Japanese Breast Cancer
Society, 2000), which are essentially the same as those of the World
Health Organization. A complete response (CR) is defined as the
disappearance of tumour; partial response (PR) refers to a
decrease in tumour size of 50% or more; no change (NC) indicates
a decrease in tumour size of 50% or less or an increase of tumour
size by less than 25%; and progressive disease (PD) indicates an
increase in tumour size of 25% or more.
The grading of the pathological efficiency of chemotherapy,
which was evaluated microscopically by a skilled pathologist, was
also categorised according to the criteria established by the
Japanese Breast Cancer Society (The Japanese Breast Cancer
Society, 2000). The three grades are defined as follows: Grade 3 is
the complete disappearance of variable cancer cells on the
examined specimens; Grade 2, the apparent degeneration of two
out of three or more of the population of observed cancer cells;
Grade 1, the presence of degenerated cells in less than two out of
three of examined tumour cells; and Grade 0, the presence of no
degenerative cancer cells on specimens.
Immunohistochemical assessment
All samples were retrospectively processed with haematoxylin–
eosin staining, negative control staining, and immunostaining
for TP in our laboratory. Thymidine phosphorylase antibody
was obtained from Roche Diagnostics (Basel, Switzerland), and the
method for immunohistochemistry followed the protocol given
in the immunohistochemistry kit ‘Anti-TP Antibody, Formalin-
Grade’ (Roche Diagnostics Corporation, USA). The TP-stained
slides were assessed for tumour cells and stromal cells according
to the criteria defined in the kit. Staining intensities were scored
as one of the four grades 0, 1þ,2 þ, and 3þ, and staining
patterns were scored as one of the five grades 0, 1þ,2 þ,3 þ,
and 4þ.
Oestrogen receptor (ER) status progesterone receptor (PR) was
also determined by an immunohistochemical method as described
previously (Saji et al, 2002). Tumours containing 10% or more
receptor-positive cells were scored as being receptor-positive.
Statistical methods
All patients with tissue staining data were included in the analysis.
The statistical analyses for the TP-immunostained preparations
were conducted as follows. The four grades of staining intensities
were scored as 0, 1, 2, and 3. Similarly, the five grades of staining
patterns were scored as 0, 1, 2, 3, and 4. Thymidine phosphorylase
up- or down-regulation was evaluated as the difference between
the sample score after chemotherapy minus the sample score prior
to chemotherapy for each patient. Samples with score differences
greater than 1 were evaluated as ‘upregulated’, and less than  1a s
‘downregulated.’ Score differences in the range between  1 and 1
were evaluated as ‘no change.’ Scores of staining intensities and
staining patterns were analysed, and the summation of staining
intensity and pattern scores were also analysed. After checking the
distribution of the score differences, the t-test was used to compare
the means.
For the contingency tables, Fisher’s exact test was used to assess
the potential different distribution. To relate the score differences
with the treatment groups, we used the Mantel–Haenszel test for
contingency tables and the t-test to compare the means. Since the
known prognostic factors such as tumour size were distributed
differently in each treatment group, tumour size was used as a
stratified factor for both the Mantel–Haenszel and t-test.
Bonferroni’s correction was applied to adjust the P-values of the
pairwise comparisons between each treatment group.
All analyses were carried out by using SAS 8.2, and alpha was
set at 0.05.
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lRESULTS
Patient characteristics
A total of 92 patients were enrolled in this study. All the 92 patients
were eligible and provided tissue staining results. The patient
characteristics are shown in Table 1. Imbalances were observed for
tumour size and number of patients, n, between the treatment
groups, which would not affect the results of the present study,
because no correlation was observed with TP regulation as
reported below. At initial diagnosis, the average age of the women
in this study was 51 years (range, 28–74 years). With respect to
tumour size, those of 11 patients were less than 3.0cm and those of
81 patients were greater than 3.1cm. In all, 79% of patients had
positive nodal status and 64.1% of patients had oestrogen-
receptor-positive tumours.
Among the patients, 14 were treated with AC or EC, 58 were
treated with FAC or FEC, and 20 were treated with the
TXT-containing regimen.
Thymidine phosphorylase immunohistochemistry
We used the difference in each patient’s tissue staining scores
before and after chemotherapy to assess TP up- or down-
regulation (Figure 1). Thymidine phosphorylase scores, staining
intensities, and staining patterns from both tumour cells and
stromal cells were available. No correlations were observed
between the tumour and stromal scores. TP changes were seen
in response to chemotherapy; TP levels in tumour and stromal
cells were upregulated in 50 patients (54.4%) and 30 patients
(32.6%), and downregulated in 15 patients (16.3%) and 29 patients
(31.5%), respectively.
Table 2 shows the correlation between TP changes and patients’
characteristics (Table 2A: tumour, 2B: stroma, respectively). An
association between them was seen only in tumour size for stromal
TP (P¼0.020). On the other hand, there were no significant
differences for relationships for the number of nodes involved, ER
status, or menopausal status.
Table 3 shows the relation between TP changes and treatment
groups. TP changes were lowest in the FAC/FEC group and highest
in the AC/EC group. Adjusted P-values of pairwise comparisons by
Bonferroni’s correction suggest that the TP score changes in the
FAC/FEC group are significantly different from those in the AC/EC
group (tumour: P¼0.0001, stromal: P¼0.0001). Nevertheless, no
association was observed between scores of tumour and stroma,
and the association with treatment regimen was similar for both
tumour and stroma.
In the AC or EC group, TP was upregulated in the tumour and
stromal cells of 92.9 and 85.7% of patients, respectively; however,
Table 1 Patients’ characteristics and overall response rate
Regimen (%)
Characteristics n AC/EC FAC/FEC TXT P-value*
Menopausal status
Pre 46 5 (10.9) 27 (58.7) 14 (30.4)
Post 46 9 (19.6) 31 (67.4) 6 (13.0) 0.107
Tumour size
 3.0cm 11 0 (0.0) 2 (18.2) 9 (81.8)
3.1cm- 81 14 (17.3) 56 (69.1) 11 (13.6) o0.001
Number of nodes involved
0 19 4 (21.1) 5 (26.3) 10 (52.6)
1–3 18 2 (11.1) 9 (50.0) 7 (38.9)
4– 55 8 (14.6) 44 (80.0) 3 (5.4) o0.001
Oestrogen receptor
+ 59 9 (15.3) 35 (59.3) 15 (25.4)
  33 5 (15.2) 23 (69.7) 5 (15.1) 0.571
Progesterone receptor
+ 39 6 (15.4) 26 (66.7) 7 (17.9)
  53 8 (15.1) 32 (60.4) 13 (24.5) 0.789
Cycle (median) 92 2–4 (4.0) 2–6 (3.0) 7–8 (8.0) —
Response rate 92 50.0% 41.4% 70.0% —
(95% CI) (23.0–77.0) (28.6–55.1) (45.7–88.1) —
AC¼adriamycin (ADR) and cyclophosphamide (CPA); EC¼epirubicin (EPI) and
CPA; FAC¼5-fluorouracil (5-FU), ADR, and CPA; FEC¼5-FU, EPI, and CPA,
TXT¼docetaxel-containing regimen, CI¼confidence interval, *Fisher’s exact test.
Figure 1 TP expression status of pre- and post-treatment. (A) An invasive ductal carcinoma: TP expression was upregulated remarkably by the treatment
with FEC (5-FU, epirubicin, and cyclophosphamide) followed by docetaxel. Tumour TP score: pretreatment; 0 (upper), post-treatment; 7 (bottom), yielding
a score difference of 7. The treatment achieved PR. (B) An invasive ductal carcinoma; TP expression was not changed remarkably by the treatment with FEC
followed by docetaxel. Tumour TP score: pretreatment; 6 (upper), post-treatment; 5 (bottom), yielding a score difference of  1. The treatment achieved
PR.
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group, tumour TP was upregulated in 41.4% of patients and
downregulated in 20.7%. In the TXT-containing regimen, tumour
TP was upregulated in 65.0% of patients and downregulated in
15.0%.
Clinical response rates
Of the 92 patients available for analysis, an overall response rate
(ORR) of of 50.0%. (95% confidence interval (CI): 23.0–77.0%)
was achieved by patients who were treated with AC or EC, an ORR
of 41.4% (95% CI: 28.6–55.1%) by the patients treated with FAC or
FEC, and an ORR of 70.0% (95% CI: 45.7–88.1%) by those patients
given the TXT-containing regimen, as shown in Table 1.
The relationship between ORR and TP status is shown in Table 4.
There was no correlation observed between clinical response and
TP status, for either tumour or stromal cells (P¼0.383 and
P¼0.461, respectively).
Pathological response rate
Of the 87 patients available for analysis, a grade 2 response was
achieved by 14.3%. of patients who were treated with AC or EC
(95% CI: 1.78–42.8%), 12.1% of those treated with FAC or FEC
(95% CI: 4.99–23.3%), and 6.7% of those treated with the TXT-
containing regimen (95% CI: 0.17–32.0%). Overall, a grade 2
response of 11.5% (95% CI: 5.65–20.1%) was seen in this study.
There was no significant correlation between the pathological
responses of grade 2 and TP changes in both tumour and stromal
cells (P¼0.600 and P¼0.273, respectively).
DISCUSSION
Although the predictive value of TP expression in tumour tissues
has been studied extensively for 5-FU or 5-FU-containing
treatments, there is still little known about changes in TP levels
in human tumours in response to chemotherapy. In this study, we
showed that TP expression is often enhanced in primary breast
Table 2 Association of (A) tumour TP changes and (B) stromal TP
changes with patients’ characteristics
(A) Tumour TP changes
Tumour TP
Up (%) NC (%) Down (%) P-value*
Menopausal status
Pre 29 (63.0) 9 (19.6) 8 (17.4)
Post 21 (45.7) 18 (39.1) 7 (15.2) 0.122
Tumour size
Median (range) 6.2 (1.5–18.0)
 3.0cm 6 (54.6) 2 (18.2) 3 (27.3)
3.1cm – 44 (54.3) 25 (30.9) 12 (14.8) 0.456
Number of nodes involved
0 13 (68.4) 5 (26.3) 1 (5.3)
1–3 9 (50.0) 5 (27.8) 4 (22.2)
4– 28 (50.9) 17 (30.9) 10 (18.2) 0.578
Oestrogen receptor
Positive 36 (61.0) 16 (27.1) 7 (11.9)
Negative 14 (42.4) 11 (33.3) 8 (24.2) 0.157
(B) Stromal TP changes
Stromal TP
Up (%) NC (%) Down (%) P-value*
Menopausal status
Pre 15 (32.6) 16 (34.8) 15 (32.6)
Post 15 (32.6) 17 (37.0) 14 (30.4) 1.000
Tumour size
Median (range) 6.2 (1.5–18.0)
 3.0cm 0 (0.0) 7 (63.6) 4 (36.4)
3.1cm– 30 (37.0) 26 (32.1) 25 (30.9) 0.020
Number of nodes involved
0 10 (52.6) 3 (15.8) 6 (31.6)
1–3 4 (22.2) 9 (50.0) 5 (27.8)
4– 16 (29.1) 21 (38.2) 18 (32.7) 0.173
Oestrogen receptor
Positive 21 (35.6) 20 (33.9) 18 (30.5)
Negative 9 (27.3) 13 (39.4) 11 (33.3) 0.736
TP¼thymidine phosphorylase; Up¼upregulated; NC¼no change; Down¼down-
downregulated; *Fisher’s exact test.
Table 3 Tumour TP changes by each regimen
Regimen n
Gain in
TP score
(mean) Up (%) NC (%) Down (%)
AC/EC
Tumour 14 4.3 13 (92.9) 1 (7.1) 0 (0.0)
Stroma 14 3.6 12 (85.7) 2 (14.3) 0 (0.0)
FAC/FEC
Tumour 58 0.7 24 (41.4) 22 (37.9) 12 (20.7)
Stroma 58  0.9 10 (17.2) 25 (43.1) 23 (39.7)
TXT-containing
regimen
Tumour 20 1.8 13 (65.0) 4 (20.0) 3 (15.0)
Stroma 20 0.0 8 (40.0) 6 (30.0) 6 (30.0)
Total
Tumour 92 — 50 (54.4) 27 (29.3) 15 (16.3)
Stroma 92 — 30 (32.6) 33 (35.9) 29 (31.5)
Tumour Stroma
Regimen
compared
t-test M–H t-test M–H
AC/EC vs FAC/FEC o0.0001 0.0114 o0.0001 o0.0001
FAC/FEC vs TXT 0.2287 0.5700 0.0580 0.0021
AC/EC vs TXT 0.1527 0.5616 0.0339 0.7773
Up¼upregulated; NC¼no change; Down¼downregulated; AC¼adriamycin
(ADR) and cyclophosphamide (CPA); EC¼epirubicin (EPI) and CPA; FAC¼5-
fluorouracil (5-FU), ADR, and CPA; FEC¼5-FU, EPI, and CPA; P-values with
Bonferroni’s correction, adjusted by tumour size; M–H¼Mantel–Haenszel test.
Table 4 Relationship between TP changes and response
n Up (%) NC (%) Down (%) P-value*
Tumour
Responder 45 24 (53.3) 16 (35.6) 5 (11.1)
Nonresponder 47 26 (55.3) 11 (23.4) 10 (21.3) 0.383
Stroma
Responder 45 14 (31.1) 14 (31.1) 17 (37.8)
Nonresponder 47 16 (34.0) 19 (40.5) 12 (25.5) 0.461
Up¼upregulated; NC¼no change; Down¼downregulated; *Mantel–Haenszel
test adjusted by tumour size.
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we found that TP was frequently upregulated in response to
treatment by an EC/AC- or TXT-containing regimen. These results
seem to be compatible with the data for human cancer xenograft
experiments where taxanes, CPA, and mitomycin-C showed the
potent ability to upregulate TP (Sawada et al, 1998; Endo et al,
1999). TXT also caused TP upregulation as a neoadjuvant in
advanced breast cancer patients (Kurosumi et al, 2000), a result
that also seems to be compatible with the clinical data. Thymidine
phosphorylase in tumour cells tended to be co-upregulated with
TP in tumour-associated stromal cells such as macrophages,
indicating a possible role for microenvironmental factors in this
response. In previous studies looking at correlations between TP
and various immune mediators in the human breast tumour
microenvironment, TP expression was associated significantly
with expressions of TNF-a (Leek et al, 1998), IL-1a (Eda et al,
1993), and monocyte chemoattractant protein (MCP)-1 (Saji et al,
2002). From the molecular profile, it is known that multiple copies
of potential Sp-1 binding sites are clustered upstream of the start
site for the initiation of TP transcription (Zhu et al, 2002).
Therefore, it is possible that TP upregulation would be triggered by
increases in the intratumoural concentrations of these immune
mediators in response to chemotherapy. As chemotherapy causes
massive damage in tumour cells, the immune cells, especially
macrophages, are activated to eliminate the damaged cells. In this
process, it is estimated that large amounts of chemical immune
mediators are produced by tumour-associated macrophages in the
tumour microenvironment. Since hypoxia and hypoglucose are
also characterised as stimuli of TP expression (Griffiths et al,
1997), these physical factors might help to enhance TP expression
in association with local hyper-cytokinaemia.
For those patients treated with FAC or FEC, the 5-FU-containing
regimens, we found no increased frequency of TP upregulation
after chemotherapy. There are at least two possible explanations
for this phenomenon. Firstly, the high concentration of 5-FU might
downregulate TP expression. It is known that high concentrations
of pyrimidine substrate change or downregulate the expression
levels of nucleoside metabolism enzymes. There are few reports
investigating the effect of high concentrations of 5-FU on TP;
however, this mechanism is likely to be involved.
Secondarily, 5-FU might selectively kill or suppress TP-over-
expressing cells. Many basic and clinical studies have indicated
that 5-FU-contaning regimens are more effective for TP-over-
expressing tumour cells as compared with TP-less-expressing
tumour cells (Fox et al, 1997; Evrard et al, 1999; Gasparini et al,
1999; Morita et al, 2001; Yang et al, 2002). Therefore, these two
scenarios should be further studied. Thymidine phosphorylase is
stress-induced and, basically, TP is shown to be an enzyme that
contributes to cell survival, because 2-DDR, a metabolite of
thymidine via TP, induces neovascularisation and contributes to
antiapoptosis (Haraguchi et al, 1994). After exposure to che-
motherapy, TP might also function as mechanism for survival by
the tumour cells. Based upon this hypothesis, a sequential
treatment consisting of TP-upregulating chemotherapy followed
by TP-dependent chemotherapy, such as by capecitabine, might be
a reasonable therapeutic approach. In fact, the combination
treatment with taxane and capecitabine showed a synergistic effect
in animal experiments (Sawada et al, 1998) and induced a
significant improvement in the survival of metastatic breast cancer
patients (O’Shaughnessy et al, 2002). Therefore, the examination of
TP expression in detail might provide various ideas to consider
about optimal combinations in dosage and timing between
capecitabine and other chemotherapeutic drugs. For example, a
TC or TAC regimen might be promising to induce maximal TP
expression. Furthermore, in cases where TP is not upregulated
after the initial chemotherapy, the subsequent capecitabine
monotherapy might not be effective.
In conclusion, TP is frequently up- or down-regulated after EC/
AC- or taxane-containing chemotherapy in primary breast tumour
tissues. The upregulated levels of TP are less for 5-FU-containing
regimens. Thymidine phosphorylase is indeed upregulated by
several anticancer drugs in human breast cancer cells, including
both tumour and stromal cells; however, there are variations in the
level. Thus, it is important to consider an individual strategy for
sensitisation of breast tumour tissues to 5-FU by chemotherapy
through TP.
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